Shares of Sarepta Therapeutics advanced after the company said it has received the go-ahead from U.K. regulators to keep dosing in a study of its Elevidys treatment for Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Sarepta Therapeutics shares were higher after J.P. Morgan reduced its December 2025 price target to $84 from $169 and maintained its overweight rating. The stock was up 4% to $39.55 Tuesday and is ...

As the U.S. market experiences a slight dip following a strong rally in the S&P 500, investors are closely monitoring economic indicators and broader market sentiment that impact small-cap companies.